Skip to content
DataLookout
Menu

OSONENCT03976180

High-flow Oxygen for Vaso-occlusive Pain Crisis

StatusUnknown
PhaseNot applicable
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 6 versions: 6 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Recruiting
  2. Notable Primary and study completion dates pushed to Nov 27, 2025
    • Eligibility criteria expanded, about 32 words
    v6
  3. Notable Trial status: Not Yet Recruiting to Recruitingv5 Show 4 more changesShow less
    • Primary completion date: May 14, 2021 to Nov 10, 2021
    • Study sites: 0 to 1
    • Study completion date: May 29, 2021 to Nov 27, 2021
    • Start date changed from estimate of Feb 1, 2020 to Apr 27, 2020
  4. Notable Start date: Dec 1, 2019 to Feb 1, 2020
    • Primary completion date: Mar 14, 2021 to May 14, 2021
    • Study completion date: Mar 29, 2021 to May 29, 2021
    v4
  5. Notable Start date: Sep 1, 2019 to Dec 1, 2019v3
  6. Notable Start date: Jun 1, 2019 to Sep 1, 2019
    • Primary completion date: Dec 14, 2020 to Mar 14, 2021
    • Study completion date: Dec 29, 2020 to Mar 29, 2021
    v2
  7. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Rate of cardiac and neurologic related events (Pilot Stage)
Timeframe: At the end end of the "pilot stage" and up to 28 days
Rate of vaso-occlusive pain crisis (VOC) resolution without complication (Activity stage)
Timeframe: Day 5
Rate of secondary acute chest syndrome (ACS)(Efficacy Stage)
Timeframe: Day 14

Secondary (12)

Volume of transfused red blood cells and volume of exsanguinated blood
Pain intensity evaluated by categorical pain score
Pain intensity evaluated by visual analogue scale
VOC duration
VOC-free days
Show 7 moreShow less
Reticulocyte count
Arterial blood gas
Cumulative doses of intravenous and subcutaneous opioids
Number of complicated VOC
Duration of hospital stay
Number of re-hospitalizations or emergency department consultations for VOC or ACS
Number of death (Mortality)

Arms and interventions

standard low-flow oxygenActive comparator

In the control group, standard low-flow oxygen will be delivered via nasal prongs (LFNO), up to hospital discharge or secondary ACS onset, in order to achieve normoxia (target pulse oxymetry saturation of 95%). This strategy is in accordance with current recommendations and usual care;

HFNO with low FiO2 (21%-30%)Experimental

HFNO with low FiO2 (21%-30%) targeting normoxia: to test the effect of improved pulmonary function;

HFNO with intermediate FiO2 (50%)Experimental

HFNO with intermediate FiO2 (50%): to test the combined effect of improved pulmonary function and moderate hyperoxia; in this group, FiO2 will be set at 50% during the first 24 hours of intervention to target moderate hyperoxia, then reduced to 21-30% during the following 48 hours to target normoxia

HFNO with high FiO2 (100%)Experimental

HFNO with high FiO2 (100%): to test the combined effect of improved pulmonary function and intense hyperoxia; in this group, FiO2 will be set at 100% during the first 24 hours of intervention to target intense hyperoxia, then reduced to 21-30% during the following 48 hours to target normoxia

Devices: Stadard low-flow oxygen, HFNO with low FiO2 (21%-30%), HFNO with intermediate FiO2 (50%), HFNO with high FiO2 (100%)

Sites

1 site in 1 country

  • Henri MondorCréteil, France